drugset / Trial / NCT03790839
Drug Interaction Study Between Dorzagliatin and Sitagliptin
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and sitagliptin given alone and in combination will be studied.
Timeline
- Start
- 2019-01-31
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dorzagliatin | Small molecule | 75 mg | — |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
Indications
No indication recorded.